81 related articles for article (PubMed ID: 24928441)
1. The polycomb group protein EZH2 inhibits lung cancer cell growth by repressing the transcription factor Nrf2.
Li Z; Xu L; Tang N; Xu Y; Ye X; Shen S; Niu X; Lu S; Chen Z
FEBS Lett; 2014 Aug; 588(17):3000-7. PubMed ID: 24928441
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells.
Kikuchi J; Takashina T; Kinoshita I; Kikuchi E; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Marquez VE; Nishimura M; Dosaka-Akita H
Lung Cancer; 2012 Nov; 78(2):138-43. PubMed ID: 22925699
[TBL] [Abstract][Full Text] [Related]
3. EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors.
Fillmore CM; Xu C; Desai PT; Berry JM; Rowbotham SP; Lin YJ; Zhang H; Marquez VE; Hammerman PS; Wong KK; Kim CF
Nature; 2015 Apr; 520(7546):239-42. PubMed ID: 25629630
[TBL] [Abstract][Full Text] [Related]
4. Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function.
Wan L; Xu K; Wei Y; Zhang J; Han T; Fry C; Zhang Z; Wang YV; Huang L; Yuan M; Xia W; Chang WC; Huang WC; Liu CL; Chang YC; Liu J; Wu Y; Jin VX; Dai X; Guo J; Liu J; Jiang S; Li J; Asara JM; Brown M; Hung MC; Wei W
Mol Cell; 2018 Jan; 69(2):279-291.e5. PubMed ID: 29351847
[TBL] [Abstract][Full Text] [Related]
5. Polycomb repressive complex's evolutionary conserved function: the role of EZH2 status and cellular background.
Gall Trošelj K; Novak Kujundzic R; Ugarkovic D
Clin Epigenetics; 2016; 8():55. PubMed ID: 27239242
[TBL] [Abstract][Full Text] [Related]
6. Mutual regulation between CHD5 and EZH2 in hepatocellular carcinoma.
Xie CR; Li Z; Sun HG; Wang FQ; Sun Y; Zhao WX; Zhang S; Zhao WX; Wang XM; Yin ZY
Oncotarget; 2015 Dec; 6(38):40940-52. PubMed ID: 26517514
[TBL] [Abstract][Full Text] [Related]
7. Targeting EZH2-mediated methylation of H3K27 inhibits proliferation and migration of Synovial Sarcoma in vitro.
Shen JK; Cote GM; Gao Y; Choy E; Mankin HJ; Hornicek FJ; Duan Z
Sci Rep; 2016 Apr; 6():25239. PubMed ID: 27125524
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma.
Lewis PW; Müller MM; Koletsky MS; Cordero F; Lin S; Banaszynski LA; Garcia BA; Muir TW; Becher OJ; Allis CD
Science; 2013 May; 340(6134):857-61. PubMed ID: 23539183
[TBL] [Abstract][Full Text] [Related]
9. Macrophage/microglial Ezh2 facilitates autoimmune inflammation through inhibition of Socs3.
Zhang X; Wang Y; Yuan J; Li N; Pei S; Xu J; Luo X; Mao C; Liu J; Yu T; Gan S; Zheng Q; Liang Y; Guo W; Qiu J; Constantin G; Jin J; Qin J; Xiao Y
J Exp Med; 2018 May; 215(5):1365-1382. PubMed ID: 29626115
[TBL] [Abstract][Full Text] [Related]
10. NIPBL-mediated RAD21 facilitates tumorigenicity by the PI3K pathway in non-small-cell lung cancer.
Xu X; Wang D; Xu W; Li H; Chen N; Li N; Yao Q; Chen W; Zhong J; Mao W
Commun Biol; 2024 Feb; 7(1):206. PubMed ID: 38378967
[TBL] [Abstract][Full Text] [Related]
11. A549 cell proliferation inhibited by RNAi mediated silencing of the Nrf2 gene.
Zhang B; Xie C; Zhong J; Chen H; Zhang H; Wang X
Biomed Mater Eng; 2014; 24(6):3905-16. PubMed ID: 25227109
[TBL] [Abstract][Full Text] [Related]
12. EZH2, the moderator in the discussion between methyltransferases at histone H3?
Cho Y; Swarnabala S; Lockey RF; Kolliputi N
J Cell Commun Signal; 2015 Mar; 9(1):77-9. PubMed ID: 25381642
[No Abstract] [Full Text] [Related]
13. c-Rel regulates Ezh2 expression in activated lymphocytes and malignant lymphoid cells.
Neo WH; Lim JF; Grumont R; Gerondakis S; Su IH
J Biol Chem; 2014 Nov; 289(46):31693-31707. PubMed ID: 25266721
[TBL] [Abstract][Full Text] [Related]
14. The acetyltransferase p300 regulates NRF2 stability and localization.
Ganner A; Pfeiffer ZC; Wingendorf L; Kreis S; Klein M; Walz G; Neumann-Haefelin E
Biochem Biophys Res Commun; 2020 Apr; 524(4):895-902. PubMed ID: 32057361
[TBL] [Abstract][Full Text] [Related]
15. miR‑144‑3p regulates the resistance of lung cancer to cisplatin by targeting Nrf2.
Yin Y; Liu H; Xu J; Shi D; Zhai L; Liu B; Wang L; Liu G; Qin J
Oncol Rep; 2018 Dec; 40(6):3479-3488. PubMed ID: 30542710
[TBL] [Abstract][Full Text] [Related]
16. Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway.
Leone A; Roca MS; Ciardiello C; Terranova-Barberio M; Vitagliano C; Ciliberto G; Mancini R; Di Gennaro E; Bruzzese F; Budillon A
Free Radic Biol Med; 2015 Dec; 89():287-99. PubMed ID: 26409771
[TBL] [Abstract][Full Text] [Related]
17. Long Noncoding RNA SOX2OT Ameliorates Sepsis-Induced Myocardial Injury by Inhibiting Cellular Pyroptosis Through Mediating the EZH2/Nrf-2/NLRP3 Signaling Pathway.
Bai X; Yang L; Liu R; Tang Y; Yang L; Ma L; Chen M; Zhang L
J Inflamm Res; 2024; 17():3115-3127. PubMed ID: 38774445
[TBL] [Abstract][Full Text] [Related]
18. Tumor-suppressive functions of protein lysine methyltransferases.
Aziz N; Hong YH; Kim HG; Kim JH; Cho JY
Exp Mol Med; 2023 Dec; 55(12):2475-2497. PubMed ID: 38036730
[TBL] [Abstract][Full Text] [Related]
19. Phytochemical Profiles and Anticancer Effects of
Ruangsuriya J; Sichaem J; Tantraworasin A; Saeteng S; Wongmaneerung P; Inta A; Davies NM; Inthanon K
Scientifica (Cairo); 2023; 2023():6613670. PubMed ID: 37520043
[TBL] [Abstract][Full Text] [Related]
20. Regulation of Keap1-Nrf2 axis in temporal lobe epilepsy-hippocampal sclerosis patients may limit the seizure outcomes.
Kishore M; Pradeep M; Narne P; Jayalakshmi S; Panigrahi M; Patil A; Babu PP
Neurol Sci; 2023 Dec; 44(12):4441-4450. PubMed ID: 37432566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
